PharmaEssentia
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel chec… Read more
PharmaEssentia (6446) - Total Assets
Latest total assets as of September 2025: NT$34.45 Billion TWD
Based on the latest financial reports, PharmaEssentia (6446) holds total assets worth NT$34.45 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
PharmaEssentia - Total Assets Trend (2010–2024)
This chart illustrates how PharmaEssentia’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
PharmaEssentia - Asset Composition Analysis
Current Asset Composition (September 2024)
PharmaEssentia's total assets of NT$34.45 Billion consist of 81.8% current assets and 18.2% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 67.8% |
| Accounts Receivable | NT$2.69 Billion | 8.7% |
| Inventory | NT$1.28 Billion | 4.1% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$272.72 Million | 0.9% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how PharmaEssentia's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PharmaEssentia's current assets represent 81.8% of total assets in 2024, an increase from 54.4% in 2010.
- Cash Position: Cash and equivalents constituted 67.8% of total assets in 2024, up from 19.7% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 36.0% in 2010.
- Asset Diversification: The largest asset category is accounts receivable at 8.7% of total assets.
PharmaEssentia Competitors by Total Assets
Key competitors of PharmaEssentia based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
PharmaEssentia - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - PharmaEssentia generates 0.31x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, PharmaEssentia generates $9.55 in net profit.
PharmaEssentia - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.83 | 12.31 | 3.82 |
| Quick Ratio | 6.54 | 11.67 | 3.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$22.91 Billion | NT$ 22.69 Billion | NT$ 3.06 Billion |
PharmaEssentia - Advanced Valuation Insights
This section examines the relationship between PharmaEssentia's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.14 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | 13.9% |
| Total Assets | NT$31.06 Billion |
| Market Capitalization | $5.84 Billion USD |
Valuation Analysis
Below Book Valuation: The market values PharmaEssentia's assets below their book value (0.19 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: PharmaEssentia's assets grew by 13.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for PharmaEssentia (2010–2024)
The table below shows the annual total assets of PharmaEssentia from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-09-30 | NT$31.06 Billion | +13.91% |
| 2023-09-30 | NT$27.27 Billion | +77.85% |
| 2022-09-30 | NT$15.33 Billion | +147.37% |
| 2021-09-30 | NT$6.20 Billion | +12.06% |
| 2020-09-30 | NT$5.53 Billion | +86.90% |
| 2019-09-30 | NT$2.96 Billion | +5.50% |
| 2018-09-30 | NT$2.81 Billion | -23.55% |
| 2017-09-30 | NT$3.67 Billion | -18.44% |
| 2016-09-30 | NT$4.50 Billion | +332.30% |
| 2015-09-30 | NT$1.04 Billion | -37.27% |
| 2014-09-30 | NT$1.66 Billion | -24.86% |
| 2013-09-30 | NT$2.21 Billion | +200.87% |
| 2012-09-30 | NT$733.74 Million | +94.71% |
| 2011-09-30 | NT$376.85 Million | +21.50% |
| 2010-09-30 | NT$310.16 Million | -- |